

956-34 Effect of Time to Thrombolytic Therapy on Infarct Size Assessed by Tomographic Sestamibi Perfusion Imaging

Raymond J. Gibbons, Robin S. Roberts, Timothy F. Christian, Salim Yusuf for the CORE Investigators. *Mayo Clinic, McMaster University; Hamilton, Ontario, CANADA*

Previous attempts to demonstrate an association between infarct size (as assessed by left ventricular function) and the duration of chest pain prior to initiation of thrombolytic therapy have yielded conflicting results. The CORE trial is an international, randomized dose-ranging trial of poloxamer 188 which randomized 2,954 patients with acute myocardial infarction (< 12 hours' duration) between 5/4/94 and 6/25/95. A substudy used tomographic sestamibi perfusion imaging to assess infarct size in 1,180 patients. Of these patients, 1065 received acute thrombolytic therapy (streptokinase or t-PA) and had analyzable images. Infarct size as a percent of the left ventricle was measured using previously established techniques at a central laboratory. The time to thrombolytic therapy was significantly (p = 0.014) associated with infarct size:

Time to Thrombolysis	n	Infarct Size (% LV)
< 2 hours	309	19.5 ± 18.8
2-4 hours	396	22.5 ± 20.0
4-12 hours	360	23.9 ± 20.5

After adjustment for infarct location, prior infarct, thrombolytic and dose of poloxamer 188, time remained significant (p = 0.027). However, a 2 hr increase in time was associated with an increase in infarct size of only 1.1% of the LV, compared to an increase of 8.1% for prior infarction and 16.7% for anterior infarction.

Conclusion: Time to initiation of thrombolytic therapy is a significant determinant of infarct size as assessed by tomographic sestamibi perfusion imaging in the CORE trial. The magnitude of its effect is small compared to prior infarction or infarct location.

956-35 The Fate of Patients With a Previous Stroke Given Thrombolysis for Acute Myocardial Infarction

Solomon Behar, David Tarme, Hanoeh Hod, Valentina Boyko, Shmuel Gottlieb. *Neufeld Cardiac, Research Institute, Sheba Medical Center, Tel Hashomer, Israel*

Patients (pts) with a history of stroke (HS) have a relative contraindication for thrombolytic therapy (TT) after acute myocardial infarction (AMI). We compared the characteristics and outcome of pts with HS treated or not treated with TT among 2010 unselected pts after AMI, hospitalized in 25 CCUs in Israel.

	HS and TT (n = 29)	HS without TT (n = 87)	p
Men (%)	76	72	NS
Age (mean ± s.d.)	72 ± 10 yrs	67 ± 10 yrs	0.01
Diabetes (%)	24	40	NS
Hypertension (%)	59	63	NS
Recurrent MI	34	41	NS
CHF/P/Edema (%)	21	21	NS
PAF (%)	10	18	NS
Cardiogenic shock (%)	14	7	NS
Stroke (%)	3	2	NS
Coronary angiography (%)	14	14	NS
PTCA/CABG (%)	3	10	NS
30-day mortality (%)	14	23	NS

The overall incidence of stroke was similar in both groups. No cases of intracranial hemorrhage were observed among pts treated with TT. After adjustment for age, CHF, diabetes and PAF, the 30-day mortality odds ratio for those treated with TT was 0.63 (90%CI 0.18-2.15). This study suggests that selected pts with HS may benefit from TT.

956-36 Fibrinolytics vs Primary Angioplasty in Acute Myocardial Infarction (FAP): A Randomized Trial in a Community Hospital in Argentina

Liliana Grinfeld, Daniel Berrocal, Jorge Belardi, Alejandro Spinetta, Carlos Rojas Matas, Pablo Oberti, Hernan Doval, Oscar Bazzino, Arturo Cagide. *Hospital Italiano de Buenos Aires, Argentina*

Percutaneous transluminal coronary angioplasty (PTCA) has become an alternative to thrombolytics as initial approach in the treatment of acute myocardial infarction (AMI). The purpose of this study was to determine if primary PTCA: 1) was feasible in our media and 2) could improve the clinical and angiographic outcome. Patients (p) within 12 hrs of an AMI, eligible for thrombolysis, were included. Exclusion criteria were cardiogenic shock, and

LLBBB. The end points were: 1) 50% reduction of ST elevation in the EKG at 120 minutes after randomization and 2) presence of TIMI 3 flow in the infarct related artery in the angiogram prior to discharge. A composite of in-hospital clinical events (death, extension of MI, development of heart failure, stroke and major bleeding) was a secondary end point. From 10/93 to 8/95, 112 p were randomized to streptokinase (SK) 1.5 K U (58 p) or primary PTCA (54 p). Baseline clinical and infarct location characteristics were similarly distributed in both groups. The mean age was 66 ± 23 years, with 71% male gender. The time from the onset of symptoms to randomization was 242 ± 138 min for PTCA and 258 ± 162 for SK (p = NS). The angiographic success for PTCA was 91%. The interval of time from symptoms onset to ST 50% decrease was 325 ± 144 min for PTCA and 334 ± 151 for SK (p = NS). Resolution of ST at 120 min was 79.6% for PTCA and 50% for SK (p = 0.002). In hospital mortality was 9.2% for PTCA and 10.3% for SK (p = NS). Angiographic follow-up was obtained in 83% of the p in a mean of 8 ± 4 days. TIMI 3 flow was found in 95% for PTCA and 63.6% for SK (p = 0.001). The combined end point of major events was 12.9% for PTCA and 25.8% for SK (p = NS). Thus event free survival was 87% and 74% respectively. **Conclusions:** 1) In this study primary PTCA was feasible and as save as SK. 2) PTCA showed a significantly: a) greater resolution in ST changes and b) greater incidence of TIMI 3 flow in the infarct related artery prior to discharge than SK. 3) In hospital major events showed a tendency to be reduced with PTCA.

957 Prognosis Following Acute Myocardial Infarction

Tuesday, March 26, 1996, Noon-2:00 p.m.
Orange County Convention Center, Hall E
Presentation Hour: Noon-1:00 p.m.

957-22 Non Q-Wave Myocardial Infarction Post Thrombolysis. What Are They Really? (How Should They Be Classified?)

Robert Dupuis, Claude Lauzon, Richard F. Davies, Mario Talajic, Duncan J. Stewart, Wayne J. Warnica, Martin Gardner, Bruce Sussex, Pierre Savard, Etel Mikes, John Ferguson, Jean L. Rouleau. *Theford Mines, Quebec, Canada*

Non Q-wave MI (NQ) differ from Q-wave MI (Q) for their natural evolution. Thrombolysis (TL) has increased the number of NQ resulting from aborted transmural MI. How do they evolve and how should they be classified remains unclear. CAMI is a Canadian multicenter study where 4133 consecutive MI were prospectively recruited between 1990 and 1992. Transferred patients (1007) were excluded and 2368 accepted a complete follow-up. We compared Q and NQ with or without TL.

Variables	Q post		NQ post		NQ No TL		p	
	TL (1)	TL (2)	TL (3)	TL (4)	1 vs 3	3 vs 4		
N (%)	1003 (32)	760 (24)	339 (11)	1024 (33)				
21 days death*	69 (6.9)	115 (15)	24 (7.1)	98 (9.6)	NS	NS		
1 y. death*	105 (11)	162 (21)	38 (11)	182 (18)	NS	NS		
1 y. rec MI**	60 (7.6)	52 (9.3)	26 (9.6)	67 (9.0)	NS	NS		
1 y. rec Ang**	375 (47)	269 (48)	150 (55)	384 (52)	#	NS		
PTCA (1 y.)**	227 (29)	104 (19)	90 (33)	158 (21)	NS	NS		
CABG (1 y.)**	87 (11)	74 (13)	36 (13)	131 (18)	NS	NS		

*On total cohort (3126), ** with complete follow-up, #p < 0.05, &p < 0.01

All groups showed significant baseline characteristic differences. Previous MI, PTCA and CABG conferred a much higher risk to develop a NQ either with or without TL. TL was the most important prognostic factor and both groups post TL (Q or NQ) showed identical outcome (cf Table).

We conclude that NQ post TL behave like Q post TL and has a much better prognosis than NQ without TL. Therefore they should be considered either as a special category of MI or together with Q for future studies.

957-23 Nonfatal Reinfarction as an Independent Riskfactor for Subsequent Mortality in Post-Myocardial Infarction Patients

Ron T. van Domburg, Jaap W. Deckers, Aida J. Azar, Paul F.M.M. van Bergen, Jan J.C. Jonker. *University Hospital Dijkzigt and Erasmus University Rotterdam, The Netherlands*

The independent risk carried by nonfatal reinfarction for subsequent death has seldom been quantified. The prognostic significance of nonfatal reinfarction was determined from the ASPECT trial database. From 1986 till 1992 3404 post-myocardial infarction patients were assigned to long-

TUESDAY POSTER